DE602006009834D1 - Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung - Google Patents

Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung

Info

Publication number
DE602006009834D1
DE602006009834D1 DE602006009834T DE602006009834T DE602006009834D1 DE 602006009834 D1 DE602006009834 D1 DE 602006009834D1 DE 602006009834 T DE602006009834 T DE 602006009834T DE 602006009834 T DE602006009834 T DE 602006009834T DE 602006009834 D1 DE602006009834 D1 DE 602006009834D1
Authority
DE
Germany
Prior art keywords
inflammable
autoimmune
antagonists
treatment
eye disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602006009834T
Other languages
German (de)
English (en)
Inventor
Daniel J Cua
Robert A Kastelein
Van T Tsai
Rachel Caspi
Phyllis Silver
Dror Luger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
US Department of Health and Human Services
Original Assignee
Schering Corp
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37686002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE602006009834(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp, US Department of Health and Human Services filed Critical Schering Corp
Publication of DE602006009834D1 publication Critical patent/DE602006009834D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE602006009834T 2005-09-01 2006-08-30 Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung Active DE602006009834D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71379205P 2005-09-01 2005-09-01
US83731206P 2006-08-11 2006-08-11
PCT/US2006/033840 WO2007027761A2 (en) 2005-09-01 2006-08-30 Use of il-23 and il-17 antagonists to treat autoimmune ocular inflammatory disease

Publications (1)

Publication Number Publication Date
DE602006009834D1 true DE602006009834D1 (de) 2009-11-26

Family

ID=37686002

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602006009834T Active DE602006009834D1 (de) 2005-09-01 2006-08-30 Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung

Country Status (21)

Country Link
US (6) US20080199460A1 (enExample)
EP (3) EP2116258A1 (enExample)
JP (3) JP2009507023A (enExample)
CN (1) CN101296706B (enExample)
AT (1) ATE445415T1 (enExample)
AU (1) AU2006284841B2 (enExample)
BR (1) BRPI0615297A2 (enExample)
CA (1) CA2621086A1 (enExample)
CY (1) CY1110606T1 (enExample)
DE (1) DE602006009834D1 (enExample)
DK (1) DK1933869T3 (enExample)
ES (1) ES2333260T3 (enExample)
HR (1) HRP20100014T1 (enExample)
NO (1) NO20081574L (enExample)
NZ (2) NZ595262A (enExample)
PL (1) PL1933869T3 (enExample)
PT (1) PT1933869E (enExample)
RS (1) RS51142B (enExample)
SI (1) SI1933869T1 (enExample)
TW (2) TWI463993B (enExample)
WO (1) WO2007027761A2 (enExample)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1954719A2 (en) 2005-12-02 2008-08-13 Genentech Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
JP2009540018A (ja) 2006-06-13 2009-11-19 ザイモジェネティクス， インコーポレイテッド Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
US7767206B2 (en) 2006-10-02 2010-08-03 Amgen Inc. Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto
CN101668531B (zh) * 2007-02-28 2014-05-07 默沙东公司 用于治疗免疫病症的联合治疗
EP2150564A2 (en) * 2007-04-27 2010-02-10 ZymoGenetics, Inc. Antagonists to il-17a, il-17f, and il-23p19 and methods of use
EP3246045B1 (en) * 2007-07-26 2025-09-03 Osaka University Therapeutic agents for ocular inflammatory disease comprising interleukin 6 receptor inhibitor as active ingredient
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
CA2706200A1 (en) * 2007-11-27 2009-06-04 Ablynx N.V. Immunoglobulin constructs comprising multiple single variable domains and an fc portion
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
CA2711696C (en) 2008-01-09 2021-10-26 Reza Dana Therapeutic compositions for treatment of ocular inflammatory disorders
CN104151428B (zh) * 2008-02-21 2017-07-14 麒麟-安姆根有限公司 Il‑17ra‑il‑17rb拮抗物及其用途
NZ588674A (en) 2008-05-05 2013-02-22 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
EP2385839B1 (en) * 2009-01-09 2014-11-26 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20120014970A1 (en) * 2009-01-09 2012-01-19 Reza Dana Therapeutic Compositions for Treatment of Corneal Disorders
WO2010114859A1 (en) * 2009-04-01 2010-10-07 Genentech, Inc. Treatment of insulin-resistant disorders
SG175276A1 (en) 2009-05-05 2011-11-28 Novimmune Sa Anti-il-17f antibodies and methods of use thereof
EP2480251B1 (en) 2009-09-21 2025-12-03 Peptinov Carrier conjugates of il-23-peptides and their induced antibodies
EP2523688B1 (en) 2010-01-15 2017-10-11 Kirin-Amgen, Inc. Antibody formulation and therapeutic regimens
US20110311527A1 (en) * 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
CA2806438C (en) 2010-07-29 2021-04-13 Eleven Biotherapeutics, Inc. Chimeric il-1 receptor type i agonists and antagonists
JP5537740B2 (ja) * 2010-10-08 2014-07-02 ノバルティス アーゲー Ｉｌ−１７アンタゴニストを用いて乾癬を治療する方法
PE20141162A1 (es) 2010-11-04 2014-09-18 Boehringer Ingelheim Int Anticuerpos anti-il-23
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
WO2013059644A1 (en) * 2011-10-21 2013-04-25 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
CN104245738B (zh) 2012-04-05 2018-02-02 弗·哈夫曼-拉罗切有限公司 针对人tweak和人il17的双特异性抗体及其用途
KR102124758B1 (ko) 2012-05-03 2020-06-19 베링거 인겔하임 인터내셔날 게엠베하 항-ｉｌ-23ｐ19 항체
JP6362587B2 (ja) 2012-05-22 2018-07-25 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｉｌ−１７ａ／ｆｉｌ−２３二重特異性抗体およびその使用
EP2931311A4 (en) * 2012-12-13 2016-08-17 Merck Sharp & Dohme LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
WO2014107737A2 (en) * 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
JP6450364B2 (ja) 2013-03-13 2019-01-09 セセン バイオ， インコーポレイテッド 眼送達のためのキメラサイトカイン製剤
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
WO2016014775A1 (en) 2014-07-24 2016-01-28 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of il-23a related diseases
UA123624C2 (uk) 2014-09-03 2021-05-05 Бьорінґер Інґельхайм Інтернаціональ Ґмбх Сполука, специфічна до іл-23а та фнп-альфа, та її застосування
AR102417A1 (es) * 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
EP3193901B1 (en) 2014-12-23 2018-04-04 4D Pharma Research Limited Pirin polypeptide and immune modulation
LT3065748T (lt) 2014-12-23 2018-03-12 4D Pharma Research Limited Bacteroides thetaiotaomicron padermė ir jos panaudojimas uždegimo sumažinimui
EP3928827A1 (en) 2014-12-31 2021-12-29 Stimwave Technologies Incorporated Antenna assembly
JP2018506275A (ja) * 2015-01-28 2018-03-08 ジェネンテック， インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
SG11201705728RA (en) 2015-02-04 2017-08-30 Boehringer Ingelheim Int Methods of treating inflammatory diseases
CN104725514A (zh) * 2015-02-06 2015-06-24 中国药科大学 新型il23拮抗剂
SMT202200174T1 (it) 2015-06-15 2022-05-12 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
SG10201912323VA (en) 2015-06-15 2020-02-27 4D Pharma Res Ltd Compositions comprising bacterial strains
PL3307288T3 (pl) 2015-06-15 2019-12-31 4D Pharma Research Limited Kompozycje zawierające szczepy bakteryjne
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
JP6909208B2 (ja) * 2015-09-17 2021-07-28 アムジェン インコーポレイテッド Ｉｌ２３経路バイオマーカーを使用するｉｌ２３アンタゴニストに対する臨床応答の予測
HK1254843B (zh) 2015-11-20 2020-04-17 希杰生物科技株式会社 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) * 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
EP3520801A1 (en) 2016-03-04 2019-08-07 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
TWI802545B (zh) 2016-07-13 2023-05-21 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
JP7212945B2 (ja) 2017-05-22 2023-01-26 フォーディー ファーマ リサーチ リミテッド 細菌株を含む組成物
EP3630942B1 (en) 2017-05-24 2022-11-30 4D Pharma Research Limited Compositions comprising bacterial strain
MA49425A (fr) 2017-06-14 2020-04-22 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
TWI767013B (zh) 2017-06-14 2022-06-11 英商4D製藥研究有限公司 包含細菌品系之組成物
MA49373B1 (fr) 2017-06-14 2021-02-26 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN120058945A (zh) * 2020-08-05 2025-05-30 辛德凯因股份有限公司 受体配对相关的组合物和方法
KR20250127176A (ko) 2020-08-05 2025-08-26 신테카인, 인크. IL27Rα 결합 분자 및 사용 방법
US12012457B1 (en) 2020-08-05 2024-06-18 Synthekine, Inc. IL23R binding molecules and methods of use
US12234291B2 (en) 2020-08-05 2025-02-25 Synthekine, Inc. IL2RB binding molecules and methods of use
US12122839B2 (en) 2020-08-05 2024-10-22 Synthekine, Inc. IFNGR binding synthetic cytokines and methods of use
US12018085B2 (en) 2020-08-05 2024-06-25 Synthekine, Inc. Interferon-gamma R2 (IFNGR2) binding molecules comprising single-domain antibodies and method of use thereof to treat autoimmune and inflammatory diseases
KR20230061393A (ko) 2020-08-05 2023-05-08 신테카인, 인크. IL10Rb 결합 분자 및 사용 방법
EP4192502A4 (en) 2020-08-05 2024-10-09 Synthekine, Inc. Compositions and methods related to il27 receptor binding
JP7767391B2 (ja) 2020-08-05 2025-11-11 シンセカイン インコーポレイテッド ＩＬ１０Ｒａ結合分子および使用方法
US11859001B2 (en) 2020-08-05 2024-01-02 Synthekine, Inc. IL12RB1-Binding molecules and methods of use
MX2023001491A (es) 2020-08-05 2023-03-08 Synthekine Inc Moleculas de union a gp130 y metodos de uso.
AU2021321525A1 (en) 2020-08-05 2023-03-30 Synthekine, Inc. IL10 receptor binding molecules and methods of use
US12291572B2 (en) 2020-08-05 2025-05-06 Synthekine, Inc. IL12 receptor synthetic cytokines and methods of use
WO2022031884A2 (en) 2020-08-05 2022-02-10 Synthekine, Inc. Il2rg binding molecules and methods of use
KR20240082379A (ko) * 2021-10-03 2024-06-10 시스트이뮨, 인코포레이티드 암 치료 방법 및 이의 약제학적 조성물

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
ATE427968T1 (de) 1992-08-21 2009-04-15 Univ Bruxelles Immunoglobuline ohne leichtkette
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
ES2162863T3 (es) 1993-04-29 2002-01-16 Unilever Nv Produccion de anticuerpos o fragmentos (funcionalizados) de los mismos derivados de inmunoglobulinas de cadena pesada de camelidae.
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
JP4373495B2 (ja) 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6680057B1 (en) * 1995-03-23 2004-01-20 Immunex Corporation Methods of treating autoimmune disease by administering interleukin-17 receptor
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
WO2000032634A1 (en) 1998-12-01 2000-06-08 Protein Design Labs, Inc. Humanized antibodies to gamma-interferon
WO2002008285A2 (en) 2000-06-22 2002-01-31 Amgen, Inc. Il-17 molecules and uses thereof
WO2002097048A2 (en) 2001-05-30 2002-12-05 Centocor, Inc. ANTI-p40 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
WO2003086310A2 (en) 2002-04-12 2003-10-23 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
WO2004042009A2 (en) * 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
WO2004071517A2 (en) * 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
TWI439285B (zh) 2003-03-10 2014-06-01 Merck Sharp & Dohme Ｉｌ－２３激動劑及拮抗劑之用途及相關試劑
AU2004239288B2 (en) * 2003-05-09 2010-01-28 Centocor, Inc. IL-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
MX341074B (es) 2003-07-08 2016-08-05 Genentech Inc Polipeptidos heterologos il-17 a/f y usos terapeuticos de los mismos.
US20050287593A1 (en) * 2004-05-03 2005-12-29 Schering Corporation Use of cytokine expression to predict skin inflammation; methods of treatment
CN1993480A (zh) * 2004-05-03 2007-07-04 先灵公司 Il－17表达预测皮肤炎症的用途；治疗方法
ATE476993T1 (de) 2004-06-07 2010-08-15 Univ Ramot Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
JP2008505080A (ja) * 2004-07-01 2008-02-21 ニューヨーク ユニバーシティー ＲＯＲγｔ機能の調節のための組成物および方法
DE102005032499B4 (de) * 2004-07-13 2009-10-22 Lg Electronics Inc. Dämpfer zur Vibrationsdämpfung und damit ausgerüstete Waschmaschine
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
CA2587590A1 (en) * 2004-11-19 2006-06-08 Synta Pharmaceuticals Corp. Pyrimidine compounds and uses thereof
MX2007006214A (es) * 2004-11-24 2008-04-16 Therakine Ltd Un implante para suministro de farmaco intraocular.
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
JP2008523842A (ja) 2004-12-21 2008-07-10 セントカー・インコーポレーテツド 抗ｉｌ−１２抗体、エピトープ、組成物、方法および用途
TW200641353A (en) 2005-02-14 2006-12-01 Wyeth Corp Interleukin-17F antibodies and other IL-17F signaling antagonists and uses therefor
BRPI0611714A2 (pt) 2005-06-30 2009-01-13 Abbott Lab proteÍnas de ligaÇço a il-12/p40
PT1896073E (pt) * 2005-06-30 2013-05-28 Janssen Biotech Inc Composições, métodos e aplicações de anticorpos anti-il-23
ME02705B (me) 2005-08-31 2017-10-20 Merck Sharp & Dohme Inženjerisana anti-il-23 antitela
PT2548577T (pt) 2005-12-29 2017-05-29 Janssen Biotech Inc Anticorpos humanos anti-il-23, composições, métodos e usos
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds

Also Published As

Publication number Publication date
AU2006284841A1 (en) 2007-03-08
EP1933869B1 (en) 2009-10-14
TW200800259A (en) 2008-01-01
NZ595262A (en) 2013-03-28
ATE445415T1 (de) 2009-10-15
EP2322219A2 (en) 2011-05-18
HK1119578A1 (en) 2009-03-13
WO2007027761A2 (en) 2007-03-08
RS51142B (sr) 2010-10-31
US20100111954A1 (en) 2010-05-06
CN101296706B (zh) 2011-11-30
ES2333260T3 (es) 2010-02-18
US20140248279A1 (en) 2014-09-04
US20110142831A1 (en) 2011-06-16
JP2011184466A (ja) 2011-09-22
JP5462838B2 (ja) 2014-04-02
WO2007027761A3 (en) 2007-05-03
US20080199460A1 (en) 2008-08-21
TWI463993B (zh) 2014-12-11
US20130323251A1 (en) 2013-12-05
CN101296706A (zh) 2008-10-29
NO20081574L (no) 2008-05-30
JP2009507023A (ja) 2009-02-19
EP1933869A2 (en) 2008-06-25
PT1933869E (pt) 2009-12-24
US8524230B2 (en) 2013-09-03
US20100111950A1 (en) 2010-05-06
JP2014005285A (ja) 2014-01-16
SI1933869T1 (sl) 2010-02-26
DK1933869T3 (da) 2010-03-01
PL1933869T3 (pl) 2010-06-30
TW201235050A (en) 2012-09-01
BRPI0615297A2 (pt) 2011-05-17
HRP20100014T1 (hr) 2010-02-28
EP2322219A3 (en) 2013-06-05
TWI372061B (en) 2012-09-11
EP2116258A1 (en) 2009-11-11
AU2006284841B2 (en) 2012-11-08
NZ566424A (en) 2011-10-28
CA2621086A1 (en) 2007-03-08
CY1110606T1 (el) 2015-04-29

Similar Documents

Publication Publication Date Title
DE602006009834D1 (de) Verwendung von il-23 und il-17-antagonisten zur behandlung von autoimmuner entzündlicher augenerkrankung
NL301089I2 (nl) imlifidase
DE602004032522D1 (de) Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
CY1118902T1 (el) Ρυθμιση της δραστικοτητας των προνευροτροφινων
ATE515288T1 (de) Carboxy-amido-triazole zur lokalisierten behandlung von augenerkrankungen
MX2008006076A (es) Metodos, composiciones y kits para el tratamiento de condiciones medicas.
CY1118452T1 (el) Ενωσεις και συνθεσεις ως αναστολεις πρωτεϊνικης κινασης
EA201892431A1 (ru) Олигонуклеотиды для лечения заболевания глаз
EP1916964A4 (en) IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
MY198928A (en) B7-h3 antibody, antigen-binding fragment thereof and medical use thereof
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
DE502005011119D1 (enExample)
CY1115891T1 (el) Φαρμακευτικες συνθεσεις για την αντιμετωπιση των διαταραχων του εσω ωτος
ATE413162T1 (de) Pharmazeutische zusammensetzungen zur sicheren verabreichung von bei der behandlung von drogenabhängigkeit verwendeten arzneimitteln
EP3351211C0 (en) SCLERAL PROSTHESIS TO TREAT PRESBYOPIA AND OTHER EYE DISORDERS
HK1253734A1 (zh) 用作RORγ激动剂和用於治疗疾病的芳基二氢-2H-苯并[B][1，4]恶嗪磺酰胺和相关化合物
ATE521608T1 (de) Glucokinaseaktivatoren
ATE534391T1 (de) 3,11b-cis-dihydrotetrabenazin zur behandlung von psychosen
ATE456955T1 (de) Verwendung von cyclodextrin zur behandlung und vorbeugung von entzündlichen bronchialerkrankungen
DE602007011975D1 (de) Thiadiazolderivate zur behandlung neurodegenerativer krankheiten
DE602004021847D1 (de) Verfahren zur prävention und behandlung von diabetes mit neurturin
CY1110043T1 (el) 2-αμινοβενζουλ παραγωγα
ATE542535T1 (de) Verwendung von azapaullonen zur vorbeugung und behandlung pankreatischer autoimmunkrankheiten
JOP20210009A1 (ar) طرق لعلاج HFpEF باستعمال داباجليفلوزين وتركيبات تشمله
BRPI0517972A (pt) ácido 5,6,7-triidroxiheptanóico e análogos para o tratamento de doenças oculares e doenças associadas com respostas hiperproliferativas e angiogênicas

Legal Events

Date Code Title Description
8363 Opposition against the patent